These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2663216)

  • 1. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
    Mathé G; Reizenstein P; Eriguchi M
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):75-92. PubMed ID: 2663216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials of the treatment of minimal residual tumours.
    Mathé G; Reizenstein P; Eriguchi M
    Drugs Exp Clin Res; 1986; 12(1-3):83-98. PubMed ID: 3525078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
    Mathé G; Reizenstein P; Eriguchi M
    Suppl J Med Oncol Tumor Pharmacother; 1988; 1():75-92. PubMed ID: 3074229
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
    Smith RE; Colangelo L; Wieand HS; Begovic M; Wolmark N
    J Natl Cancer Inst; 2004 Aug; 96(15):1128-32. PubMed ID: 15292384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy and the kinetic refractoriness of minimal residual tumors.
    Reizenstein P; Mathé G
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):57-8. PubMed ID: 2743532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why complete or partial response can not be achieved by immunotherapy].
    Fujimoto S; Nitta K
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):459-63. PubMed ID: 1690966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New survival curve model for comparison of adjuvant therapy of malignant diseases.
    Eriguchi M; Mathé G
    Biomed Pharmacother; 1986; 40(4):143-7. PubMed ID: 3790708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curative cancer chemotherapy.
    Frei E
    Cancer Res; 1985 Dec; 45(12 Pt 1):6523-37. PubMed ID: 2998603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive, adoptive, and active immunotherapy: a review of clinical trials in cancer.
    Mathé G
    Cancer Detect Prev Suppl; 1987; 1():279-90. PubMed ID: 3319146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
    Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
    Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of chemotherapy in adjuvant treatment of breast cancer: modulation of the immune status].
    Fargeot P; Guerrin J
    Bull Cancer; 1984; 71(4):346-53. PubMed ID: 6388673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.